Robert Hromas
Board Member & Scientific Co-founder Dialectic Therapeutics
Seminars
Tuesday 28th October 2025
Pre-Clinical & Clinical Development of DT-2216, A Selective & Potent BCL-XL Degrader for Cancer Therapy
2:30 pm
